Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS
Status:
Withdrawn
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test feasibility of measuring flumazenil-induced changes in
cortical GABA levels observed with localized 1H-MRS in relation to changes in severity of
hepatic encephalopathy (HE) in subjects with non-alcoholic liver cirrhosis. This study is a
double-blind, placebo-controlled, randomized, cross-over design.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Yale University
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)